| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 151, Issue 7 3719-3727, Copyright © 1993 by American Association of Immunologists
ARTICLES |
WJ Storkus, HJ Zeh 3d, MJ Maeurer, RD Salter and MT Lotze
Department of Surgery, University of Pittsburgh School of Medicine, PA 15261.
Using a newly described pH 3.3 acid elution technique, peptides were extracted by denaturation of class I molecules on the surface of human melanomas. HPLC fractionation of this material revealed six T cell epitopes (termed P1-P6) recognized by HLA-A2-restricted, melanoma- specific tumor infiltrating lymphocyte (TIL) lines. Three of these fractions (P1, P2, and P4) appeared to represent shared/immunodominant melanoma Ag recognized in the context of HLA-A2 because they were expressed by 4/4 HLA-A2+ melanoma cell lines and were each recognized by all four oligoclonal HLA-A2-restricted TIL lines examined. Interestingly, P1 and P2 (but not P3-P6) could also be recognized by these same TIL when presented by the HLA-Aw69 class I molecule, which is closely related to HLA-A2. P3, P5, and P6 displayed more restricted expression and were differentially recognized by the four oligoclonal TIL lines. These results suggest that synthetic peptide derived from P1, P2, and P4 sequences (when deduced) may form the basis of effective prophylactic or therapeutic melanoma vaccines by stimulating CD8+ CTL in HLA-A2+ individuals. This approach of identifying T cell epitopes presented by class I molecules should prove generally applicable to the study of other tumors recognized by class I-restricted CTL.
This article has been cited by other articles:
|
|
 |
|
  H. Komita, X. Zhao, J. L. Taylor, L. J. Sparvero, A. A. Amoscato, S. Alber, S. C. Watkins, A. D. Pardee, A. K. Wesa, and W. J. Storkus CD8+ T-Cell Responses against Hemoglobin-{beta} Prevent Solid Tumor Growth Cancer Res., October 1, 2008; 68(19): 8076 - 8084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hirano, M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansen, S. Kojima, and L. M. Nadler Identification of an immunogenic CD8+ T-cell epitope derived from {gamma}-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia Blood, October 15, 2006; 108(8): 2662 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hirano, M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansen, and L. M. Nadler Efficient Presentation of Naturally Processed HLA Class I Peptides by Artificial Antigen-Presenting Cells for the Generation of Effective Antitumor Responses. Clin. Cancer Res., May 15, 2006; 12(10): 2967 - 2975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. van Baren, M.-C. Bonnet, B. Dreno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Lienard, D. Speiser, M. Marchand, V. G. Brichard, et al. Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells J. Clin. Oncol., December 10, 2005; 23(35): 9008 - 9021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Purcell and J. J. Gorman Immunoproteomics: Mass Spectrometry-based Methods to Study the Targets of the Immune Response Mol. Cell. Proteomics, March 1, 2004; 3(3): 193 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Carrabba, C. Castelli, M. J. Maeurer, P. Squarcina, A. Cova, L. Pilla, N. Renkvist, G. Parmiani, and L. Rivoltini Suboptimal Activation of CD8+ T Cells by Melanoma-derived Altered Peptide Ligands: Role of Melan-A/MART-1 Optimized Analogues Cancer Res., April 1, 2003; 63(7): 1560 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pilch, H. Hohn, K. Freitag, C. Neukirch, A. Necker, P. Haddad, B. Tanner, P. G. Knapstein, and M. J. Maeurer Improved Assessment of T-Cell Receptor (TCR) VB Repertoire in Clinical Specimens: Combination of TCR-CDR3 Spectratyping with Flow Cytometry-Based TCR VB Frequency Analysis Clin. Vaccine Immunol., March 1, 2002; 9(2): 257 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hallermalm, K. Seki, C. Wei, C. Castelli, L. Rivoltini, R. Kiessling, and J. Levitskaya Tumor necrosis factor-{alpha} induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface Blood, August 15, 2001; 98(4): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhatnagar, P. J. Milburn, M. Lobigs, R. V. Blanden, and A. M. Gautam Nonobese Diabetic Mice Display Elevated Levels of Class II-Associated Invariant Chain Peptide Associated with I-Ag7 on the Cell Surface J. Immunol., April 1, 2001; 166(7): 4490 - 4497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Colella, T. N.J. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen: Implications for Tumor Immunotherapy J. Exp. Med., April 3, 2000; 191(7): 1221 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Wang, E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen, and J. Weber Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma Clin. Cancer Res., October 1, 1999; 5(10): 2756 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. de Zoeten, V. Carr-Brendel, D. Markovic, J. Taylor-Papadimitriou, and E. P. Cohen Treatment of Breast Cancer with Fibroblasts Transfected with DNA from Breast Cancer Cells J. Immunol., June 1, 1999; 162(11): 6934 - 6941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kawashima, V. Tsai, S. Southwood, K. Takesako, A. Sette, and E. Celis Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/neu by Primary in Vitro Immunization with Peptide-pulsed Dendritic Cells Cancer Res., January 1, 1999; 59(2): 431 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Theobald, T. Ruppert, U. Kuckelkorn, J. Hernandez, A. Haussler, E. A. Ferreira, U. Liewer, J. Biggs, A. J. Levine, C. Huber, et al. The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope J. Exp. Med., September 21, 1998; 188(6): 1017 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ostankovitch, A. Buzyn, D. Bonhomme, F. Connan, D. Bouscary, F. Heshmati, F. Dreyfus, J. Choppin, and J.-G. Guillet Antileukemic HLA-Restricted T-Cell Clones Generated With Naturally Processed Peptides Eluted From Acute Myeloblastic Leukemia Blasts Blood, July 1, 1998; 92(1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. de Zoeten, V. Carr-Brendel, and E. P. Cohen Resistance to Melanoma in Mice Immunized with Semiallogeneic Fibroblasts Transfected with DNA from Mouse Melanoma Cells J. Immunol., March 15, 1998; 160(6): 2915 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Uger and B. H. Barber Creating CTL Targets with Epitope-Linked {beta}2-Microglobulin Constructs J. Immunol., February 15, 1998; 160(4): 1598 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Michie, J. R. Carlyle, and J. C. Zuniga-Pflucker Early Intrathymic Precursor Cells Acquire a CD4low Phenotype J. Immunol., February 15, 1998; 160(4): 1735 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cox, J Skipper, Y Chen, R. Henderson, T. Darrow, J Shabanowitz, V. Engelhard, D. Hunt, and C. Slingluff Jr Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines Science, April 29, 1994; 264(5159): 716 - 719. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
